Skip to content
Screener

Alkermes ALKS Operating Cash Flow

Operating Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.39B-13.4%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$408.2M-5.0%
AbbVie logo
AbbVieABBV
$3.83B+134%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$20.7M+52.3%
Indivior Pharmaceuticals, Inc. logo
Indivior Pharmaceuticals, Inc.INDV
-$9M-112%
LBR
LB Pharmaceuticals IncLBRX
-$23.29M-187%

Other financials

Income statement

See full
Revenue$496.0M+27.0%
Gross profit$397.9M+16.6%
Operating income$18.4M-80.3%
Net income$501.0K-99.4%
EPS (diluted)$0.00-100%

Balance sheet

See full
Cash & equivalents$511.5M-1.9%
Total debt$1.6B+2,064%
Total equity$1.8B+11.3%
Total assets$4.4B+95.0%

Cash flow

See full
CapEx$8.1M-37.4%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$8.32B+89.9%
Enterprise value$9.38B+139%
P/E125.9×+113×
P/S+2.1×

Profitability

See full
Gross margin84.6%-0.6pp
Operating margin7%-17.8pp
Net margin4%-19.2pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity3.9%-20.1pp
Debt / equity0.9×+0.8×
Current ratio2.3×-0.9×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: Alkermes’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206534
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Contract liabilities359
Operating lease liabilities(2,773)(2,548)
Other long-term liabilities4,8892,851
Cash flows (used in) provided by operating activities(165,743)98,811
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions of property, plant and equipment(4,090)(10,110)
Proceeds from the sale of property, plant and equipment91,713
Business combination, net of cash acquired(2,085,073)

Item 1. Condensed Consolidated Financial Statements:

FAQ

What is Alkermes's operating cash flow?
Alkermes (ALKS) reported operating cash flow of -$165.74M in Q1 2026.
How has Alkermes's operating cash flow changed year-over-year?
Alkermes's operating cash flow decreased by 267.7% year-over-year, from $98.81M to -$165.74M.
What is the long-term trend for Alkermes's operating cash flow?
Over 3 years (2021 to 2025), Alkermes's operating cash flow has grown at a 72.4% compound annual growth rate (CAGR), from $101.72M to $520.75M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about Alkermes's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude